Targeting HTR2B suppresses nonfunctioning pituitary adenoma growth and sensitizes cabergoline treatment via inhibiting Gαq/PLC/PKC γ /STAT3 axis
Neuro-Oncology · 04.11.2024 · 26 (11) · 2010-2026
DOI: 10.1093/neuonc/noae130 ↗Kurz gefasst
Fachartikel in der Zeitschrift Neuro-Oncology, online erschienen am 11.07.2024. Verfasst von Shaojian Lin und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, Center of Pituitary Tumor, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. Hauptthemen laut MEDLINE: Pituitary Neoplasms, STAT3 Transcription Factor, Cabergoline, Receptor, Serotonin, 5-HT2B. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Natural Science Foundation of China, National Research Center for Translational Medicine.
Abstract (Originalsprache)
Background
Managing nonfunctioning pituitary adenomas (NFPAs) is difficult due to limited drug treatments. Cabergoline’s (CAB) effectiveness for NFPAs is debated. This study explores the role of HTR2B in NFPAs and its therapeutic potential.
Methods
We conducted screening of bulk RNA-sequencing data to analyze HTR2B expression levels in NFPA samples. In vitro and in vivo experiments were performed to evaluate the effects of HTR2B modulation on tumor growth and cell cycle regulation. Mechanistic insights into the HTR2B-mediated signaling pathway were elucidated using pharmacological inhibitors and molecular interaction assays.
Results
Elevated HTR2B expression was detected in NFPA samples, which was associated with increased tumor survival. Inhibition of HTR2B activity resulted in the suppression of tumor growth through modulation of the G2M cell cycle. The inhibition of HTR2B with PRX-08066 was found to block STAT3 phosphorylation and nuclear translocation by interfering with the Gαq/PLC/PKC pathway. A direct interaction between PKC-γ and STAT3 was critical for STAT3 activation. CAB was shown to activate pSTAT3 via HTR2B, reducing its therapeutic potential. However, the combination of an HTR2B antagonist with CAB significantly inhibited tumor cell proliferation in HTR2B-expressing pituitary tumor cell lines, a xenografted pituitary tumor model, and patient-derived samples. Analysis of patient-derived data indicated that a distinct molecular pattern characterized by upregulated HTR2B/PKC-γ and downregulated BTG2/GADD45A may benefit from combination treatment with CAB and PRX-08066.
Conclusions
HTR2B is a potential therapeutic target for NFPAs, and its inhibition could improve CAB efficacy. A dual therapy approach may be beneficial for NFPA patients with high HTR2B expression.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurosurgery, Center of Pituitary Tumor, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
- Department of Neurosurgery, First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
- Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, C…
- Department of Neurosurgery, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China.
- Department of Neurosurgery, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
- Department of Pathology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
ORCID-Profile: Shaojian Lin, Zhe Bao Wu
Förderung
- National Natural Science Foundation of China
- National Research Center for Translational Medicine
Zitieren
APA
Lin, S., Wang, L., Han, C., Dai, Y., Li, C., Liu, Y., Zhang, B., Huang, N., Zhang, A., Zhang, T., Wang, Y., Xie, J., Tang, H., Cheng, Y., Yao, H., Lou, M., Xue, L., & Wu, Z. B. (2024). Targeting HTR2B suppresses nonfunctioning pituitary adenoma growth and sensitizes cabergoline treatment via inhibiting Gαq/PLC/PKC γ /STAT3 axis. Neuro-Oncology, 26(11), 2010-2026. https://doi.org/10.1093/neuonc/noae130
Vancouver
Lin S, Wang L, Han C, Dai Y, Li C, Liu Y, et al. Targeting HTR2B suppresses nonfunctioning pituitary adenoma growth and sensitizes cabergoline treatment via inhibiting Gαq/PLC/PKC γ /STAT3 axis. Neuro-Oncology. 2024;26(11):2010-2026. doi:10.1093/neuonc/noae130
BibTeX
@article{Lin2024,
author = {Lin, Shaojian and Wang, Liangbo and Han, Changxi and Dai, Yuting and Li, Changsheng and Liu, Yanting and Zhang, Bo and Huang, Ning and Zhang, Anke and Zhang, Tao and Wang, Yu and Xie, Jing and Tang, Hao and Cheng, Yijun and Yao, Hong and Lou, Meiqing and Xue, Li and Wu, Zhe Bao},
title = {Targeting HTR2B suppresses nonfunctioning pituitary adenoma growth and sensitizes cabergoline treatment via inhibiting Gαq/PLC/PKC γ /STAT3 axis},
journal = {Neuro-Oncology},
year = {2024},
volume = {26},
number = {11},
pages = {2010--2026},
doi = {10.1093/neuonc/noae130}
}
EUVIMED